Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174982
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSasamoto, Naoko-
dc.contributor.authorBabic, Ana-
dc.contributor.authorRosner, Bernard A.-
dc.contributor.authorFortner, Renée T.-
dc.contributor.authorVitonis, Allison F.-
dc.contributor.authorYamamoto, Hidemi-
dc.contributor.authorFichorova, Raina N.-
dc.contributor.authorTjønneland, Anne-
dc.contributor.authorHansen, Louise-
dc.contributor.authorOvervad, Kim-
dc.contributor.authorKvaskoff, Marina-
dc.contributor.authorFournier, Agnès-
dc.contributor.authorMancini, Francesca Romana-
dc.contributor.authorBoeing, Heiner-
dc.contributor.authorTrichopoulou, Antonia-
dc.contributor.authorPeppa, Eleni-
dc.contributor.authorKarakatsani, Anna-
dc.contributor.authorPalli, Domenico-
dc.contributor.authorPala, Valeria-
dc.contributor.authorMattiello, Amalia-
dc.contributor.authorTumino, Rosario-
dc.contributor.authorGrasso, Chiara-
dc.contributor.authorOnland-Moret, N. Charlotte-
dc.contributor.authorWeiderpass, Elisabete-
dc.contributor.authorQuirós, J. Ramón-
dc.contributor.authorLuján Barroso, Leila-
dc.contributor.authorRodríguez Barranco, Miguel-
dc.contributor.authorColorado Yohar, Sandra-
dc.contributor.authorBarricarte, Aurelio-
dc.contributor.authorDorronsoro, Miren-
dc.contributor.authorIdahl, Annika-
dc.contributor.authorLundin, Eva-
dc.contributor.authorSartor, Hanna-
dc.contributor.authorKhaw, Kay-Tee-
dc.contributor.authorKey, Timothy J.-
dc.contributor.authorMuller, David C.-
dc.contributor.authorRiboli, Elio-
dc.contributor.authorGunter, Marc J.-
dc.contributor.authorDossus, Lauren-
dc.contributor.authorKaaks, Rudolf-
dc.date.accessioned2021-03-12T11:25:47Z-
dc.date.available2021-03-12T11:25:47Z-
dc.date.issued2019-04-04-
dc.identifier.issn1055-9965-
dc.identifier.urihttp://hdl.handle.net/2445/174982-
dc.description.abstractBackground: Cancer antigen 125 (CA125) is the most promising ovarian cancer screening biomarker to date. Multiple studies reported CA125 levels vary by personal characteristics, which could inform personalized CA125 thresholds. However, this has not been well described in premenopausal women. Methods: We evaluated predictors of CA125 levels among 815 premenopausal women from the New England Case Control Study (NEC). We developed linear and dichotomous (≥35 U/mL) CA125 prediction models and externally validated an abridged model restricting to available predictors among 473 premenopausal women in the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Results: The final linear CA125 prediction model included age, race, tubal ligation, endometriosis, menstrual phase at blood draw, and fibroids, which explained 7% of the total variance of CA125. The correlation between observed and predicted CA125 levels based on the abridged model (including age, race, and menstrual phase at blood draw) had similar correlation coefficients in NEC (r = 0.22) and in EPIC (r = 0.22). The dichotomous CA125 prediction model included age, tubal ligation, endometriosis, prior personal cancer diagnosis, family history of ovarian cancer, number of miscarriages, menstrual phase at blood draw, and smoking status with AUC of 0.83. The abridged dichotomous model (including age, number of miscarriages, menstrual phase at blood draw, and smoking status) showed similar AUCs in NEC (0.73) and in EPIC (0.78). Conclusions: We identified a combination of factors associated with CA125 levels in premenopausal women. Impact: Our model could be valuable in identifying healthy women likely to have elevated CA125 and consequently improve its specificity for ovarian cancer screening.-
dc.format.extent11 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherAmerican Association for Cancer Research-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1158/1055-9965.EPI-18-1120-
dc.relation.ispartofCancer Epidemiology Biomarkers & Prevention, 2019, vol. 28, num. 6-
dc.relation.urihttps://doi.org/10.1158/1055-9965.EPI-18-1120-
dc.rights(c) American Association for Cancer Research, 2019-
dc.subject.classificationMenopausa-
dc.subject.classificationCàncer d'ovari-
dc.subject.classificationNutrició-
dc.subject.otherMenopause-
dc.subject.otherOvarian cancer-
dc.subject.otherNutrition-
dc.titlePredicting circulating CA125 levels among healthy premenopausal women-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec690022-
dc.date.updated2021-03-12T11:25:47Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Infermeria de Salut Pública, Salut mental i Maternoinfantil)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
690022.pdf853.49 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.